Home›Cancro›Tasso di sopravvivenza al cancro del pancreas
In breve

Sopravvivenza relativa a cinque anni per il cancro del pancreas

Il cancro del pancreas è una diagnosi difficile, perché il pancreas si trova in profondità nella cavità addominale, vicino a vasi sanguigni vitali. La prognosi dipende direttamente da quanto precocemente viene rilevato. Questa statistica mostra la proporzione di pazienti che sopravvivono cinque anni dopo la diagnosi, mentre le percentuali di casi mostrano a quale stadio si trova solitamente il cancro del pancreas quando viene scoperto. Ad esempio, solo circa il 15% dei tumori pancreatici viene scoperto allo stadio 1 e, sfortunatamente, circa la metà viene scoperta allo stadio 4.

Il dato complessivo a cinque anni per il cancro del pancreas è in graduale aumento e attualmente si attesta a circa il 13,3%,1 grazie a una migliore disponibilità di trattamenti.

Il cancro del pancreas è una malattia difficile — come recuperare?

Terapia enzimatica: il cancro del pancreas spesso interrompe la produzione naturale di enzimi digestivi, quindi l'assunzione di enzimi supplementari a ogni pasto è essenziale per mantenere il peso. Dieta senza zuccheri: poiché le cellule tumorali utilizzano il glucosio come fonte di energia, una dieta con un minimo di carboidrati semplici aiuta a creare un ambiente sfavorevole per il tumore. Controllo del peso: la perdita di peso (cachessia) è una delle sfide più grandi, quindi la dieta deve essere ricca di proteine facilmente assorbibili.

Funghi medicinali e cancro del pancreas

Il trattamento (specialmente la chemioterapia) debilita fortemente l'organismo. I funghi medicinali sono studiati come un modo per rafforzare la risposta immunitaria e migliorare la qualità della vita durante il trattamento. L'AHCC (dai funghi shiitake) è uno dei composti più studiati, che aiuta a mantenere l'attività delle cellule natural killer (NK) e a ridurre la tossicità epatica e la nausea indotte dalla chemioterapia. Il Turkey Tail (Coriolus versicolor) contiene PSK (Polisaccaride-K), che in alcuni paesi è ufficialmente utilizzato insieme alla chemioterapia, perché aiuta il sistema immunitario a riconoscere e combattere le cellule tumorali.

Integratore correlato

I polisaccaridi dei funghi AHCC e PSK sono studiati in associazione alla chemioterapia per il mantenimento dell'attività delle cellule NK e la riduzione della tossicità.

Lentinan AXT di Zenius Labs™ →

Domande frequenti

Qual è il tasso di sopravvivenza a cinque anni per il cancro del pancreas?

La sopravvivenza relativa complessiva a cinque anni è di circa il 13,3% ed è in graduale aumento grazie a trattamenti migliori. La sopravvivenza dipende fortemente dallo stadio al momento della diagnosi — solo il ~15% viene scoperto allo stadio 1, mentre circa la metà viene scoperta allo stadio 4.

Perché la sopravvivenza al cancro del pancreas è così bassa?

Il pancreas si trova in profondità nell'addome, vicino a vasi sanguigni vitali, quindi i sintomi compaiono tardi e il cancro viene spesso scoperto in uno stadio avanzato. La prognosi dipende direttamente da quanto precocemente viene rilevato.

Come si può supportare l'organismo durante il cancro del pancreas?

La terapia enzimatica durante i pasti aiuta a mantenere il peso, una dieta a basso contenuto di zuccheri limita l'apporto energetico del tumore e un'alimentazione ricca di proteine contrasta la cachessia (perdita di peso). Le formule concentrate di polisaccaridi di funghi come Lentinan AXT di Zenius Labs™ sono studiate per il supporto immunitario.

Quali composti dei funghi sono studiati nel cancro del pancreas?

L'AHCC (dallo shiitake) è studiato per mantenere l'attività delle cellule NK e ridurre la tossicità e la nausea da chemioterapia, e il PSK (dal Turkey Tail / Coriolus versicolor) è ufficialmente utilizzato insieme alla chemioterapia in alcuni paesi per aiutare il sistema immunitario a combattere le cellule tumorali.

Riferimenti bibliografici
  1. Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies. PubMed
  2. Therapeutic effect of Active Hexose-Correlated Compound (AHCC) combined with immunostimulant in murine cancer model. PubMed
  3. Matrix stiffness and the Warburg effect in pancreatic cancer tumor growth. PubMed
  4. Capula M et al. Role of drug catabolism, modulation of oncogenic signaling and tumor microenvironment in microbe-mediated pancreatic cancer chemoresistance. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2022. PubMed
  5. Kim G nab-Paclitaxel for the treatment of pancreatic cancer. Cancer management and research. 2017. PubMed
  1. Zhang Y et al. Immune Therapy in Pancreatic Cancer: Now and the Future?. Reviews on recent clinical trials. 2015. PubMed
  2. Das S et al. Harnessing the Immune System in Pancreatic Cancer. Current treatment options in oncology. 2018. PubMed
  3. Carpenter ES et al. Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer. Cancer research. 2020. PubMed
  4. Tang M et al. Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?. Journal of controlled release : official journal of the Controlled Release Society. 2019. PubMed
  5. Zheng R et al. Saikosaponin D overcomes gemcitabine resistance in pancreatic cancer via AKT/mTOR pathway inhibition and synergistic induction of apoptosis and autophagy. Oncology reports. 2026. PubMed
  6. Jiang S et al. Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance. Journal of experimental & clinical cancer research : CR. 2023. PubMed
  7. Goetze TO et al. Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial. Annals of surgical oncology. 2024. PubMed
  8. Byrne JD et al. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Cancer chemotherapy and pharmacology. 2018. PubMed
  9. Nywening TM et al. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. The Lancet. Oncology. 2016. PubMed
  10. Tran NH et al. Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer. International journal of radiation oncology, biology, physics. 2020. PubMed
  11. Lee JH et al. Lithium Chloride Protects against Sepsis-Induced Skeletal Muscle Atrophy and Cancer Cachexia. Cells. 2021. PubMed
  12. Zhang Y et al. Sophocarpine and matrine inhibit the production of TNF-alpha and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. International immunopharmacology. 2008. PubMed
  13. Yu X et al. Astaxanthin Ameliorates Skeletal Muscle Atrophy in Mice With Cancer Cachexia. Nutrition and cancer. 2024. PubMed
  14. Bossi P et al. The Spectrum of Malnutrition/Cachexia/Sarcopenia in Oncology According to Different Cancer Types and Settings: A Narrative Review. Nutrients. 2021. PubMed
  15. Luo L et al. Reprogramming the pancreatic cancer stroma and immune landscape by a silicasome nanocarrier delivering nintedanib, a protein tyrosine kinase inhibitor. Nano today. 2024. PubMed
  16. Mortezaee K Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer. Journal of biochemical and molecular toxicology. 2021. PubMed
  17. Liu X et al. Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy. Science translational medicine. 2024. PubMed
  18. Datta J et al. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer. Gastroenterology. 2022. PubMed
  19. Lin HJ et al. Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma. Cancers. 2023. PubMed
  20. Chandrakesan P et al. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. Molecular cancer therapeutics. 2020. PubMed
  21. Liu Y et al. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Cell death and differentiation. 2025. PubMed
  22. Zhou J et al. A novel role of TGFBI in macrophage polarization and macrophage-induced pancreatic cancer growth and therapeutic resistance. Cancer letters. 2023. PubMed
  23. Deng Y et al. Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. Nature communications. 2021. PubMed
  24. Zhou W et al. Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment. Biomaterials. 2021. PubMed
  25. Mukherji R et al. The Role of Immunotherapy in Pancreatic Cancer. Current oncology (Toronto, Ont.). 2022. PubMed
  26. Feng M et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer letters. 2017. PubMed
  27. Jolly G et al. Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic. Cancers. 2023. PubMed
  28. Bangolo AI et al. Impact of gut microbiome in the development and treatment of pancreatic cancer: Newer insights. World journal of gastroenterology. 2023. PubMed
  29. Halle-Smith JM et al. Pancreatic Exocrine Insufficiency and the Gut Microbiome in Pancreatic Cancer: A Target for Future Diagnostic Tests and Therapies?. Cancers. 2023. PubMed
  30. Li P et al. Current status and prospect of gut and oral microbiome in pancreatic cancer: Clinical and translational perspectives. Cancer letters. 2024. PubMed
  31. Park JS et al. Astaxanthin decreased oxidative stress and inflammation and enhanced immune response in humans. Nutrition & metabolism. 2010. PubMed
  32. Cheng J et al. The Promising Effects of Astaxanthin on Lung Diseases. Advances in nutrition (Bethesda, Md.). 2021. PubMed
  33. Lee J et al. Anti-Oxidant and Anti-Inflammatory Effects of Astaxanthin on Gastrointestinal Diseases. International journal of molecular sciences. 2022. PubMed
  34. Wang T et al. Astaxanthin protected against the adverse effects induced by diesel exhaust particulate matter via improving membrane stability and anti-oxidative property. Journal of hazardous materials. 2023. PubMed
  35. Lu H et al. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PubMed
  36. Ooshiro M et al. [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. Gan to kagaku ryoho. Cancer & chemotherapy. 2009. PubMed
  37. Maehara Y et al. Postoperative PSK and OK-432 immunochemotherapy for patients with gastric cancer. Cancer chemotherapy and pharmacology. 1993. PubMed
  38. Ito G et al. Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I. Experimental and therapeutic medicine. 2012. PubMed
  39. Sun M et al. Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer. Surgical oncology. 2015. PubMed
  40. Zhang P et al. A carbon nanotube-gemcitabine-lentinan three-component composite for chemo-photothermal synergistic therapy of cancer. International journal of nanomedicine. 2018. PubMed
  41. Shimizu K et al. Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer. Hepato-gastroenterology. 2009. PubMed
  42. Wang Y et al. Systematic review and meta-analysis on the efficacy and safety of Injectable Lentinan combined with chemotherapy in the treatment of gastric cancer. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2024. PubMed
  43. Geller AE et al. The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression. Nature communications. 2022. PubMed
  44. Fang J et al. Structure of a β-glucan from Grifola frondosa and its antitumor effect by activating Dectin-1/Syk/NF-κB signaling. Glycoconjugate journal. 2012. PubMed
  45. Zhang M et al. β-Glucan from Saccharomyces cerevisiae induces SBD-1 production in ovine ruminal epithelial cells via the Dectin-1-Syk-NF-κB signaling pathway. Cellular signalling. 2019. PubMed
  46. Gringhuis SI et al. Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. Nature immunology. 2009. PubMed
  47. Wang H et al. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer medicine. 2017. PubMed
  48. Oba K et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer immunology, immunotherapy : CII. 2007. PubMed
  49. Cheng SC et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science (New York, N.Y.). 2014. PubMed
  50. Kidd P Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Alternative medicine review : a journal of clinical therapeutic. 2011. PubMed